The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

BACKGROUND: Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhtar, Nabeel H., Khosravi-Hafshejani, Touraj, Akhtar, Daud, Dhadwal, Gurbir, Kanani, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815205/
https://www.ncbi.nlm.nih.gov/pubmed/35115035
http://dx.doi.org/10.1186/s13223-022-00650-w
Descripción
Sumario:BACKGROUND: Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. CASE PRESENTATION: We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. CONCLUSION: Here we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.

Ejemplares similares